Stephen Jolles

List of Publications by Year in Descending Order

154 papers	4,764 citations	39 h-index	64 g-index
176 ext. papers	6,105 ext. citations	5.2 avg, IF	5.67 L-index

#	Paper	IF	Citations
154	Clinical Outcome and Underlying Genetic Cause of Functional Terminal Complement Pathway Deficiencies in a Multicenter UK Cohort.. *Journal of Clinical Immunology*, **2022**, 1	5.7	0
153	COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort.. *Journal of Clinical Immunology*, **2022**, 1	5.7	0
152	Subcutaneous Gammanorm by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies.. *Clinical Immunology*, **2022**, 236, 108938	9	0
151	Mechanically ventilated patients shed high titre live SARS-CoV2 for extended periods from both the upper and lower respiratory tract.. *Clinical Infectious Diseases*, **2022**,	11.6	2
150	Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib.. *Frontiers in Pediatrics*, **2022**, 10, 837568	3.4	0
149	Fatigue Symptoms Associated With COVID-19 in Convalescent or Recovered COVID-19 Patients; a Systematic Review and Meta-Analysis. *Annals of Behavioral Medicine*, **2021**,	4.5	2
148	Treatment of chronic or relapsing COVID-19 in immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2021**,	11.5	8
147	COVID-19 Vaccine Response in People with Multiple Sclerosis. *Annals of Neurology*, **2021**, 91, 89	9.4	35
146	Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. *Leukemia and Lymphoma*, **2021**, 1-10	1.9	1
145	Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report. *Journal of Clinical Immunology*, **2021**, 42, 32	5.7	3
144	International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. *Journal of Allergy and Clinical Immunology*, **2021**,	11.5	9
143	Haematopoietic Stem Cell Transplant for Norovirus-Induced Intestinal Failure in X-linked Agammaglobulinemia. *Journal of Clinical Immunology*, **2021**, 41, 1574-1581	5.7	1
142	Medical algorithm: Diagnosis and management of antibody immunodeficiencies. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 3841-3844	9.3	1
141	Burden of nosocomial COVID-19 in Wales: results from a multicentre retrospective observational study of 2508 hospitalised adults. *Thorax*, **2021**, 76, 1246-1249	7.3	4
140	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. *Journal of Clinical Immunology*, **2021**, 41, 1633-1647	5.7	7
139	Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 520-531	11.5	142
138	Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1104-1107	11.5	4

137	Increased Respiratory Viral Detection and Symptom Burden Among Patients with Primary Antibody Deficiency: Results from the BIPAD Study. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 735-744.e6	5.4	8
136	Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. *Annals of Clinical Biochemistry*, **2021**, 58, 123-131	2.2	13
135	Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). *Rheumatology*, **2021**, 60, 4373-4378	3.9	15
134	Hematopoietic Stem Cell Transplantation Resolves the Immune Deficit Associated with STAT3-Dominant-Negative Hyper-IgE Syndrome. *Journal of Clinical Immunology*, **2021**, 41, 934-943	5.7	4
133	Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. *European Journal of Haematology*, **2021**, 106, 439-449	3.8	7
132	Examining the utility of extended laboratory panel testing in the emergency department for risk stratification of patients with COVID-19: a single-centre retrospective service evaluation. *Journal of Clinical Pathology*, **2021**,	3.9	1
131	Serum Protein Electrophoresis May Be Used as a Screening Tool for Antibody Deficiency in Children and Adolescents. *Frontiers in Immunology*, **2021**, 12, 712637	8.4	1
130	Heterozygous variants in ZBTB7A cause a neurodevelopmental disorder associated with symptomatic overgrowth of pharyngeal lymphoid tissue, macrocephaly, and elevated fetal hemoglobin. *American Journal of Medical Genetics, Part A*, **2021**,	2.5	0
129	Antibody Deficiency, Chronic Lung Disease, and Comorbid Conditions: A Case-Based Approach. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 3899-3908	5.4	0
128	Infections in secondary immunodeficiency patients treated with Privigen or Hizentra: a retrospective US administrative claims study in patients with hematological malignancies. *Leukemia and Lymphoma*, **2021**, 1-11	1.9	0
127	COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency. *Current Opinion in Allergy and Clinical Immunology*, **2021**, 21, 525-534	3.3	8
126	Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. *Lancet Infectious Diseases, The*, **2021**, 21, 1345-1347	25.5	5
125	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. *Nature*, **2020**, 583, 90-95	50.4	69
124	Improved anaphylaxis referral rates to specialized services from an Emergency Department. *Clinical and Experimental Allergy*, **2020**, 50, 973-976	4.1	1
123	European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. *Journal of Clinical Immunology*, **2020**, 40, 576-591	5.7	23
122	Human NK cell deficiency as a result of biallelic mutations in MCM10. *Journal of Clinical Investigation*, **2020**, 130, 5272-5286	15.9	15
121	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 901-911	5.4	28
120	Global immunoglobulin supply: steaming towards the iceberg?. *Current Opinion in Allergy and Clinical Immunology*, **2020**, 20, 557-564	3.3	10

119	Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. *Frontiers in Immunology*, **2020**, 11, 606333	8.4	5
118	Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. *Blood Advances*, **2020**, 4, 4136-4146	7.8	28
117	Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 479-491.e5	11.5	16
116	Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1304-1308	10.2	25
115	Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. *International Immunopharmacology*, **2019**, 71, 404-410	5.8	6
114	British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders. *Clinical and Experimental Immunology*, **2019**, 196, 328-335	6.2	6
113	Antibody deficiency in patients taking clozapine. *BMJ, The*, **2019**, 364, l483	5.9	2
112	The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. *Frontiers in Immunology*, **2019**, 10, 33	8.4	66
111	Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay. *Journal of Clinical Laboratory Analysis*, **2019**, 33, e22627	3	4
110	Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents. *Immunotherapy*, **2019**, 11, 1057-1065	3.8	1
109	Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. *Blood*, **2019**, 134, 897-897	2.2	4
108	Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders. *Blood*, **2019**, 134, 83-83	2.2	
107	Clozapine-associated secondary antibody deficiency. *Current Opinion in Allergy and Clinical Immunology*, **2019**, 19, 553-562	3.3	12
106	Clinical and laboratory features of seventy-eight UK patients with Good syndrome (thymoma and hypogammaglobulinaemia). *Clinical and Experimental Immunology*, **2019**, 195, 132-138	6.2	27
105	Chronic norovirus infection in primary immune deficiency disorders: an international case series. *Diagnostic Microbiology and Infectious Disease*, **2019**, 93, 69-73	2.9	5
104	Autoinflammation due to homozygous S208 mutation. *Annals of the Rheumatic Diseases*, **2019**, 78, 571-573	12.4	19
103	Rituximab in neurological disease: principles, evidence and practice. *Practical Neurology*, **2019**, 19, 5-20	2.4	38
102	Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. *Journal of Neurology*, **2018**, 265, 1115-1122	5.5	48

101	Measurement of Typhi Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency. *Clinical and Experimental Immunology*, **2018**, 192, 292-301	6.2	19
100	Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy. *Clinical and Experimental Immunology*, **2018**, 191, 212-219	6.2	19
99	Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. *Frontiers in Immunology*, **2018**, 9, 543	8.4	88
98	Quantification of human complement C2 protein using an automated turbidimetric immunoassay. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1498-1506	5.9	4
97	The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation. *Frontiers in Immunology*, **2018**, 9, 1837	8.4	42
96	Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital. *Current Pharmaceutical Biotechnology*, **2018**, 19, 728-733	2.6	9
95	Clozapine is associated with secondary antibody deficiency. *British Journal of Psychiatry*, **2018**, 1-7	5.4	27
94	Secondary antibody deficiency in neurology. *Current Opinion in Allergy and Clinical Immunology*, **2018**, 18, 481-488	3.3	4
93	Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. *Journal of Clinical Immunology*, **2018**, 38, 864-875	5.7	11
92	Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies. *Journal of Clinical Immunology*, **2018**, 38, 886-897	5.7	11
91	Novel STAT1 Gain-of-Function Mutation Presenting as Combined Immunodeficiency. *Journal of Clinical Immunology*, **2018**, 38, 753-756	5.7	10
90	Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity. *Journal of Immunological Methods*, **2018**, 459, 1-10	2.5	10
89	The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017. *Clinical and Experimental Immunology*, **2018**, 192, 284-291	6.2	34
88	Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie. *JDDG - Journal of the German Society of Dermatology*, **2017**, 15, 227-238	1.2	3
87	FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). *Clinical and Experimental Immunology*, **2017**, 187, 138-145	6.2	37
86	British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 938-945	5.4	86
85	Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex 10% Versus Gammaplex 5% in Subjects with Primary Immunodeficiency. *Journal of Clinical Immunology*, **2017**, 37, 301-310	5.7	7
84	European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. *JDDG - Journal of the German Society of Dermatology*, **2017**, 15, 228-241	1.2	14

83	When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. *Clinical and Experimental Immunology*, **2017**, 188, 333-341	6.2	64
82	Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. *Blood*, **2017**, 130, 2682-2688	2.2	93
81	The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. *Science Translational Medicine*, **2017**, 9,	17.5	94
80	Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. *Clinical and Experimental Immunology*, **2017**, 190, 226-234	6.2	14
79	Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials. *Journal of Clinical Immunology*, **2017**, 37, 517-518	5.7	4
78	Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic /NEMO mutations. *Blood*, **2017**, 130, 1456-1467	2.2	61
77	Skin Necrosis Following Subcutaneous Immunoglobulin (SCIg). *Journal of Clinical Immunology*, **2017**, 37, 27-28	5.7	4
76	Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 232-245	11.5	164
75	Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. *Clinical and Experimental Immunology*, **2017**, 187, 146-159	6.2	27
74	New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. *American Journal of Clinical and Experimental Immunology*, **2017**, 6, 76-83	1.2	11
73	Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency. *Journal of Clinical Pathology*, **2016**, 69, 87-8	3.9	6
72	European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. *Journal of the European Academy of Dermatology and Venereology*, **2016**, 30, 1657-1669	4.6	29
71	Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia. *Clinical and Experimental Immunology*, **2016**, 184, 73-82	6.2	18
70	Evaluation of a novel automated allergy microarray platform compared with three other allergy test methods. *Clinical and Experimental Immunology*, **2016**, 184, 1-10	6.2	30
69	Phenotypic and Functional Comparison of Class Switch Recombination Deficiencies with a Subgroup of Common Variable Immunodeficiencies. *Journal of Clinical Immunology*, **2016**, 36, 656-66	5.7	5
68	Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project. *Annals of Clinical Biochemistry*, **2015**, 52, 319-26	2.2	21
67	Current screening approaches for antibody deficiency. *Current Opinion in Allergy and Clinical Immunology*, **2015**, 15, 547-55	3.3	13
66	Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations. *Clinical and Experimental Immunology*, **2015**, 182, 302-13	6.2	22

65	Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. *Clinical and Experimental Immunology*, **2015**, 179, 146-60	6.2	94
64	C1 inhibitor deficiency: 2014 United Kingdom consensus document. *Clinical and Experimental Immunology*, **2015**, 180, 475-83	6.2	26
63	The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 yearsQ activity 2008-2012. *Clinical and Experimental Immunology*, **2014**, 175, 68-78	6.2	73
62	The evolution of cellular deficiency in GATA2 mutation. *Blood*, **2014**, 123, 863-74	2.2	153
61	Long-term efficacy, safety, and tolerability of Hizentra for treatment of primary immunodeficiency disease. *Clinical Immunology*, **2014**, 150, 161-9	9	23
60	Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). *Blood*, **2014**, 124, 2867-71	2.2	134
59	A UK national audit of hereditary and acquired angioedema. *Clinical and Experimental Immunology*, **2014**, 175, 59-67	6.2	59
58	The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis. *Clinical and Experimental Immunology*, **2014**, 177, 483-90	6.2	56
57	Calculated globulin (CG) as a screening test for antibody deficiency. *Clinical and Experimental Immunology*, **2014**, 177, 671-8	6.2	35
56	Subclinical infection and dosing in primary immunodeficiencies. *Clinical and Experimental Immunology*, **2014**, 178 Suppl 1, 67-9	6.2	10
55	7th International Immunoglobulin Conference: Foreword. *Clinical and Experimental Immunology*, **2014**, 178 Suppl 1, 1-2	6.2	
54	Immunoglobulins: current understanding and future directions. *Clinical and Experimental Immunology*, **2014**, 178 Suppl 1, 163-8	6.2	12
53	Bioavailability of IgG administered by the subcutaneous route. *Journal of Clinical Immunology*, **2013**, 33, 984-90	5.7	65
52	The variable in common variable immunodeficiency: a disease of complex phenotypes. *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 545-56; quiz 557	5.4	87
51	Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. *Neurology*, **2013**, 80, 55-61	6.5	53
50	A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). *Blood*, **2013**, 122, 112-23	2.2	83
49	Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. *ImmunoTargets and Therapy*, **2013**, 2, 125-33	9	11
48	Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. *Clinical and Experimental Immunology*, **2012**, 169, 172-81	6.2	88

47	The Construction of a Pharmacokinetic Model to Describe Intravenous and Subcutaneous Supplementation of IgG in Patients with Primary Immunodeficiency (PID). *Journal of Allergy and Clinical Immunology*, **2011**, 127, AB16-AB16	11.5	3
46	Cytotoxic T-cell lymphoma complicating common variable immunodeficiency. *Pathology*, **2011**, 43, 75-8	1.6	1
45	Efficacy and safety of Hizentra( ) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. *Clinical Immunology*, **2011**, 141, 90-102	9	90
44	Efficacy and safety of hizentra , a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. *Journal of Clinical Immunology*, **2011**, 31, 752-61	5.7	40
43	New Frontiers in Subcutaneous Immunoglobulin Treatment. *Biologics in Therapy*, **2011**, 1, 3		12
42	Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. *Advances in Therapy*, **2011**, 28, 521-33	4.1	32
41	Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. *Journal of Clinical Pathology*, **2010**, 63, 846-7	3.9	15
40	Patients with anaphylaxis in accident and emergency are not referred to specialised allergy services. *Journal of Clinical Pathology*, **2010**, 63, 375	3.9	3
39	Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. *Journal of Allergy and Clinical Immunology*, **2010**, 126, 1006-15, 1015.e1-4	11.5	50
38	Periodic fever syndromes. *Paediatrics and Child Health (United Kingdom)*, **2010**, 20, 503-508	0.6	1
37	Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. *Clinical and Experimental Immunology*, **2009**, 158 Suppl 1, 23-33	6.2	100
36	Intravenous immunoglobulins. Current understanding and future directions. *Clinical and Experimental Immunology*, **2009**, 158 Suppl 1, 68-70	6.2	16
35	A recipient of immunoglobulin from a donor who developed vCJD. *Vox Sanguinis*, **2009**, 96, 270	3.1	10
34	Nuclear factor-B is not essential for NADPH oxidase activity in neutrophils from anhidrotic ectodermal dysplasia patients. *Blood*, **2009**, 113, 5362-5363	2.2	1
33	Clinical immunology review series: an approach to the patient with anaphylaxis. *Clinical and Experimental Immunology*, **2008**, 153, 1-9	6.2	18
32	Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy. *Clinical and Experimental Immunology*, **2008**, 153, 10-8	6.2	22
31	Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. *Tuberculosis*, **2008**, 88, 197-202	2.6	23
30	Intravenous immunoglobulin and autoimmune disease. *Annals of the New York Academy of Sciences*, **2007**, 1110, 507-15	6.5	10

29	Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. *Journal of Clinical Pathology*, **2007**, 60, 715-6	3.9	19
28	Current strategies in TB immunotherapy. *Current Molecular Medicine*, **2007**, 7, 373-86	2.5	28
27	Chronic granulomatous disease caused by mutations other than the common GT deletion in NCF1, the gene encoding the p47phox component of the phagocyte NADPH oxidase. *Human Mutation*, **2006**, 27, 1218-29	4.7	41
26	Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin. *Journal of Clinical Pathology*, **2006**, 59, 1191-3	3.9	7
25	Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. *International Immunopharmacology*, **2006**, 6, 579-91	5.8	40
24	Current clinical uses of intravenous immunoglobulin. *Clinical Medicine*, **2006**, 6, 356-9	1.9	11
23	Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. *Infection and Immunity*, **2005**, 73, 6101-9	3.7	66
22	The role of complement testing in dermatology. *Clinical and Experimental Dermatology*, **2005**, 30, 321-6	1.8	1
21	Clinical uses of intravenous immunoglobulin. *Clinical and Experimental Immunology*, **2005**, 142, 1-11	6.2	221
20	Asymptomatic choroidal granulomas in common variable immunodeficiency. *Clinical and Experimental Ophthalmology*, **2005**, 33, 663-4	2.4	14
19	Drug-induced aseptic meningitis. *Expert Opinion on Drug Safety*, **2005**, 4, 285-97	4.1	36
18	Importance of trial design in studies using high-dose intravenous immunoglobulin. *British Journal of Dermatology*, **2003**, 148, 1284-5; author reply 1285-6	4	4
17	Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. *Acta Dermato-Venereologica*, **2003**, 83, 433-7	2.2	39
16	A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. *Clinical and Experimental Dermatology*, **2002**, 27, 3-7	1.8	41
15	Immunomodulatory action of intravenous immunoglobulin. *Immunology*, **2002**, 107, 387-93	7.8	129
14	Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin. *Clinical and Experimental Immunology*, **2002**, 129, 519-26	6.2	13
13	High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. *Clinical and Experimental Immunology*, **2002**, 129, 385-9	6.2	31
12	A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. *Clinical and Experimental Dermatology*, **2001**, 26, 127-31	1.8	61

11	The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. *British Journal of Dermatology*, **2000**, 142, 551-4	4	52
10	Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). *Journal of the American Academy of Dermatology*, **2000**, 43, 403-8	4.5	76
9	Drug-induced aseptic meningitis: diagnosis and management. *Drug Safety*, **2000**, 22, 215-26	5.1	89
8	Atypical C-ANCA following high dose intravenous immunoglobulin. *Journal of Clinical Pathology*, **1999**, 52, 177-80	3.9	15
7	Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris. *Journal of the American Academy of Dermatology*, **1999**, 40, 499-500	4.5	25
6	Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. *Journal of the American Academy of Dermatology*, **1999**, 40, 121-3	4.5	27
5	Dermatological uses of high-dose intravenous immunoglobulin. *Archives of Dermatology*, **1998**, 134, 80-6		134
4	Management of aseptic meningitis secondary to intravenous immunoglobulin **1998**, 316, 936-936		22
3	Human NK cell deficiency as a result of biallelic mutations in MCM10		1
2	Whole genome sequencing of a sporadic primary immunodeficiency cohort		2
1	The burden of nosocomial covid-19: results from the Wales multi-centre retrospective observational study of 2518 hospitalised adults		1